1. Home
  2. BLW vs EOLS Comparison

BLW vs EOLS Comparison

Compare BLW & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Limited Duration Income Trust

BLW

Blackrock Limited Duration Income Trust

HOLD

Current Price

$13.77

Market Cap

532.2M

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$4.80

Market Cap

444.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLW
EOLS
Founded
2003
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
532.2M
444.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BLW
EOLS
Price
$13.77
$4.80
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$18.80
AVG Volume (30 Days)
85.9K
1.5M
Earning Date
01-01-0001
03-03-2026
Dividend Yield
8.83%
N/A
EPS Growth
N/A
N/A
EPS
1.81
N/A
Revenue
N/A
$285,823,000.00
Revenue This Year
N/A
$14.00
Revenue Next Year
N/A
$16.78
P/E Ratio
$7.73
N/A
Revenue Growth
N/A
15.10
52 Week Low
$12.35
$4.68
52 Week High
$14.26
$17.12

Technical Indicators

Market Signals
Indicator
BLW
EOLS
Relative Strength Index (RSI) 50.61 29.36
Support Level $13.72 $4.68
Resistance Level $13.81 $4.96
Average True Range (ATR) 0.07 0.33
MACD 0.00 -0.03
Stochastic Oscillator 41.97 9.54

Price Performance

Historical Comparison
BLW
EOLS

About BLW Blackrock Limited Duration Income Trust

Blackrock Ltd Duration Income Trust is a diversified investment fund with an investment objective to provide current income and capital appreciation. The Fund's portfolio normally has an average portfolio duration of less than five years. The Fund may invest directly in such securities or synthetically through the use of derivatives.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: